"L’ICANS | Institut de cancérologie Strasbourg Europe est un ensemble hospitalier de référence issu de l’alliance entre le Centre Paul Strauss (CLCC) et les Hôpitaux Universitaires de Strasbourg (CHU). Il regroupe sur un même site leurs compétences, leurs équipes et leurs équipements techniques pour proposer une offre de prise en charge d’excellence en cancérologie publique, accessible à toutes les personnes malades. Ses nouvelles installations et ses équipements de dernière génération, offrent aux patients, accompagnants et visiteurs, des conditions optimales d’accueil, de sécurité et de confort. L’ICANS développe une expertise en cancérologie en matière de soins, de recherche et d’enseignement, en France et en Europe."

During the past decade, Institut de Cancerologie Strasbourg Europe conducted 91 clinical trials. In the 10-year time frame, 91 clinical trials started and 3 clinical trials were completed, i.e. on average, 3.3% percent of trials that started reached the finish line to date. In the past 5 years, 80 clinical trials started and 3 clinical trials were completed. i.e. 3.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut de Cancerologie Strasbourg Europe" #1 sponsor was "Institut de cancérologie Strasbourg Europe" with 19 trials, followed by "ARCAGY/ GINECO GROUP" with 8 trials sponsored, "UNICANCER" with 7 trials sponsored, "Hoffmann-La Roche" with 6 trials sponsored and "Centre Leon Berard" with 6 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut de Cancerologie Strasbourg Europe" #1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "Institut Bergonié" with 2 trials as a collaborator. Other collaborators include 56 different institutions and companies that were collaborators in the rest 63 trials.

According to Clinical.Site data, the most researched conditions in "Institut de Cancerologie Strasbourg Europe" are "Breast Cancer" (10 trials), "Endometrial Cancer" (3 trials), "Head and Neck Cancer" (3 trials), "Metastatic Colorectal Cancer" (3 trials) and "Soft Tissue Sarcoma" (3 trials). Many other conditions were trialed in "Institut de Cancerologie Strasbourg Europe" in a lesser frequency.

Most popular intervention types in "Institut de Cancerologie Strasbourg Europe" are "Drug" (63 trials), "Other" (24 trials), "Radiation" (4 trials), "Biological" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Chemotherapy" (3 trials), "Niraparib" (3 trials), "Avelumab" (2 trials) and "Cabozantinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institut de Cancerologie Strasbourg Europe" are 69 trials for "All" genders, 21 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Institut de Cancerologie Strasbourg Europe". 5 are not yet recruiting, 56 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Institut de Cancerologie Strasbourg Europe, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Institut de Cancerologie Strasbourg Europe, 6 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 16 trials that are defined as “Not Applicable".